Latest Videos

Recent Development of RIRS in Robotic Platforms

Sung Yong Cho, MD, PhD, Clinical Full Professor of Urology at Seoul National University Hospital in Seoul, South Korea, discusses advances in robotic platforms for retrograde intrarenal surgery (RIRS). Conventional RIR presents a number of challenges to both patient and surgeon while robotic-assisted RIR is affected only by patient respiration and irrigation.

Read More

Doctor Knows Best? Why Prostate Cancer Care Must Be Transformed Into Digital Health

In this 14-minute program presented during the 2021 Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer and supported by Siemens, Michael H. Johnson, MD, FACS, Associate Professor and Vice Chair of Urology at Washington University in St. Louis, discusses why digital health solutions must revolutionize prostate cancer care. Dr. Johnson asserts that we are at an inflection point in medicine when digital medicine has the opportunity to transform and improve patient care and treatment in ways that are both instantaneous but also far-reaching.

Read More

LUGPA Lecture: Urology Employment Issues

Panelists Dr. Evan Goldfischer, MD, MBA; Alan Walker, MHSA, FACMPE; and Allison Griffin discuss urology employment issues. Specifically, the panel covers physician recruitment, physician burnout and resilience, and staff recruitment and engagement, emphasizing employment paradigm shifts and creative, proactive solutions to today’s staffing challenges.

Read More

PSMA PET-CT: Clinical Applications

In this presentation, supported by Telix Pharmaceuticals, Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center in Myrtle Beach, South Carolina, presents advances in PSMA PET-CT imaging for staging, prognosis, and clinical management of prostate cancer. He first describes prostate cancer metastases before explaining prostate-specific membrane antigen (PMSA) and how it serves as an effective molecular target for metastatic prostate cancer. Dr. Shore reviews the pros and cons of conventional imaging techniques such as bone scintigraphy, computed tomography (CT), and multiparametric MRI (mpMRI). While treatment guidelines recommend conventional imaging, he notes that bone scans and CT positively identify less than 10% of men with biochemical recurrence and in particular lesions that are <1 cm with a PSA <20 ng/mL. He then compares the benefits of PSMA as an imaging target: it is upregulated in prostate cancer, the degree of expression is positively correlated with tumor state and higher risk of recurrence, there is a positive correlation between PSMA expression and Gleason score/grade, and it may be targeted with either a small molecule or antibody. Dr. Shore reviews numerous studies demonstrating the effectiveness of PSMA PET-CT in metastatic prostate cancer but indicates there is insufficient data on the use of PSMA PET-CT in patients with hormone-naïve disease. He then considers patient selection and points out several downsides including increased cost of care and the potential impact of health disparities. He concludes that PSMA PET-CT is particularly useful in detecting prostate cancer that is otherwise not identified by conventional imaging and in cases with low serum PSA.

Read More

Join the GRU Community

- Why Join? -